Rituximab (antiCD20 monoclonal antibody) and molecular-biological negativity in the treatment of patients with follicular lymphoma--a way to a cure?--Editorial | Rituximab (antiCD20 monoklonální protilátka) a molekulárne biologická negativita po lécbe nemocných s folikulárním lymfomem--cesta k vylécení!--Editorial.

Journal article published in 2007 by M. Trnený 

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload